Strategy Asset Managers LLC bought a new position in shares of The Clorox Company (NYSE:CLX – Get Rating) in the first quarter, HoldingsChannel reports. The fund bought 1,587 shares of the company, valued at around $221,000.
Other hedge funds and other institutional investors have also recently changed their holdings in the company. Dark Forest Capital Management LP acquired a new stake in Clorox in the third quarter worth approximately $25,000. MML Investors Services LLC increased its position in Clorox by 13.8% during the third quarter. MML Investors Services LLC now owns 10,810 shares of the company valued at $1,790,000 after purchasing an additional 1,312 shares last quarter. Wellington Management Group LLP increased its position in Clorox by 347.5% during the third quarter. Wellington Management Group LLP now owns 148,324 shares of the company valued at $24,563,000 after purchasing an additional 115,176 shares last quarter. National Asset Management Inc. increased its position in Clorox by 121.1% during the third quarter. National Asset Management Inc. now owns 8,090 shares of the company valued at $1,340,000 after purchasing an additional 4,431 shares last quarter. Finally, Corient Capital Partners LLC increased its position in Clorox by 4.4% during the third quarter. Corient Capital Partners LLC now owns 1,585 shares of the company valued at $262,000 after purchasing 67 additional shares last quarter. Institutional investors and hedge funds hold 77.28% of the company’s shares.
In other Clorox news, Director A D. David Mackay sold 1,000 shares in a trade that took place on Thursday, June 2. The stock was sold at an average price of $140.63, for a total transaction of $140,630.00. Following the transaction, the administrator now owns 600 shares of the company, valued at $84,378. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Additionally, COO Eric H. Reynolds sold 585 shares in a trade that took place on Monday, May 9. The shares were sold at an average price of $154.83, for a total value of $90,575.55. As a result of the transaction, the chief operating officer now owns 17,289 shares of the company, valued at approximately $2,676,855.87. The disclosure of this sale can be found here. 0.58% of the shares are currently held by company insiders.
CLX stock opened at $132.14 on Thursday. The company has a debt ratio of 3.28, a current ratio of 0.71 and a quick ratio of 0.40. The Clorox Company has a 1-year low of $120.50 and a 1-year high of $191.75. The company has a fifty-day moving average price of $142.61 and a two-hundred-day moving average price of $151.67. The company has a market capitalization of $16.26 billion, a price/earnings ratio of 35.81, a PEG ratio of 4.21 and a beta of 0.18.
Clorox (NYSE:CLX – Get Rating) last released its quarterly results on Monday, May 2. The company reported EPS of $1.31 for the quarter, beating the consensus estimate of $0.97 by $0.34. The company posted revenue of $1.81 billion in the quarter, compared to analysts’ estimates of $1.81 billion. Clorox had a net margin of 6.44% and a return on equity of 92.98%. In the same quarter of the previous year, the company had earned earnings per share of $1.62. As a group, analysts expect The Clorox Company to post EPS of 4.16 for the current fiscal year.
A number of research analysts have weighed in on CLX shares. StockNews.com began covering Clorox shares in a research report on Thursday, March 31. They have placed a “holding” rating on the stock. Barclays cut its price target on Clorox shares from $126.00 to $115.00 and set an “underweight” rating on the stock in a Monday May 23 research report. Deutsche Bank Aktiengesellschaft cut its target price on Clorox shares from $145.00 to $132.00 in a research report on Tuesday. JPMorgan Chase & Co. raised its price target on Clorox shares from $123.00 to $126.00 in a Thursday, April 14 research report. Finally, the Goldman Sachs Group reduced its target price on Clorox shares from $145.00 to $127.00 in a Tuesday, March 29 research report. Nine equity research analysts gave the stock a sell rating, five gave the company a hold rating and one gave the company a buy rating. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $140.69.
Profile Clorox (Get an evaluation)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle and International. The Health and Wellness segment offers cleaning products, such as laundry additives and household cleaning products, primarily under the brands Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex and Formula 409; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare and Clorox Total 360 brands; professional catering products under the Hidden Valley brand; and vitamins, minerals and supplements under the RenewLife, Natural Vitality, NeoCell and Rainbow Light brands in the United States.
Want to see which other hedge funds hold CLX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for The Clorox Company (NYSE:CLX – Get Rating).
Get news and reviews for Clorox Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Clorox and related companies with MarketBeat.com’s FREE daily newsletter.